Skip to main content

View full-text article in PMC

. 2014 Oct;58(10):5936–5942. doi: 10.1128/AAC.02922-14

TABLE 2.

Major outcomes of the three therapies

Outcome characteristic	Rate (% [no./total no.]) (95% CI)
Outcome characteristic	Standard triple therapy (n = 103)	Sequential therapy (n = 102)	Concomitant therapy (n = 102)
Eradication rate
Intention-to-treat	81.6 (84/103) (74.1–89.0)	89.2 (91/102) (83.2–95.2)	94.1 (96/102) (89.5–98.7)^a
Per-protocol	82.2 (83/101) (74.8–89.6)	90.0 (90/100) (84.1–95.9)	94.1 (96/102) (89.5–98.7)^a
Adverse events	8.7 (9/103) (3.3–14.2)	8.8 (9/102) (3.3–14.3)	13.7 (14/102) (7.0–20.4)
Compliance	99.0 (102/103) (97.1–100.9)	98.0 (100/102) (95.3–100.7)	100.0 (102/102)

^a

Significant difference compared with standard triple therapy.